Shares of Aethlon Medical (NASDAQ: AEMD) are surging 373.41% at the time of writing on Wednesday. The firm has recorded a huge volume though it doesn’t share any news in nearly a week. Earlier the firm has shared the publication of a pre-print manuscript indicating two case studies of severely ill COVID-19 sufferers treated with the Aethlon Hemopurifier.
The case study disclosed the successful withdrawal of viral-linked exosomes in the first sufferer and a 58% decline of plasma SARS-CoV-2 viral load in the second sufferer. Furthermore, the firm is expected to share fiscal fourth-quarter results on or about June 30. The stock has now gained 294.7% year to date.
Aethlon Medical (NASDAQ: AEMD) shares were soared 373.41% at the time of writing on Wednesday. Aethlon’s medical share price went from a low point around $1.22 to briefly over $3.73 in the past 52 weeks, though shares have since pulled back to $10.46. AEMD market cap has remained high, sitting at $27.89 million at the time of writing.
Aethlon Medical has recorded a trading volume of 194.08 million as compared to the average volume of 483.09K. Furthermore, shares of Aethlon Medical surged on Wednesday after the Reddit investing crowd turned its attention to a device from the medical-technology firm that demonstrated encouraging results for two COVID-19 sufferers. Moreover, some users advertise the firm’s Hemopurifier as an efficient COVID-19 therapy.